ENLIVEX THERAPEUTICS LTD (ENLV)
IL0011319527 - Common Stock
ENLV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 577 industry peers in the Biotechnology industry. ENLV has a great financial health rating, but its profitability evaluates not so good. ENLV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ENLV had negative earnings in the past year.
ENLV had a negative operating cash flow in the past year.
ENLV had negative earnings in each of the past 5 years.
ENLV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ENLV's Return On Assets of -83.71% is on the low side compared to the rest of the industry. ENLV is outperformed by 73.34% of its industry peers.
ENLV's Return On Equity of -96.79% is in line compared to the rest of the industry. ENLV outperforms 44.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -83.71% | ||
| ROE | -96.79% | ||
| ROIC | N/A |
ROA(3y)-46.68%
ROA(5y)-44.78%
ROE(3y)-56.09%
ROE(5y)-57.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ENLV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ENLV has been increased compared to 1 year ago.
The number of shares outstanding for ENLV has been increased compared to 5 years ago.
There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ENLV has an Altman-Z score of -2.55. This is a bad value and indicates that ENLV is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.55, ENLV perfoms like the industry average, outperforming 47.39% of the companies in the same industry.
There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.55 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 7.86 indicates that ENLV has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.86, ENLV is in the better half of the industry, outperforming 68.29% of the companies in the same industry.
A Quick Ratio of 7.86 indicates that ENLV has no problem at all paying its short term obligations.
ENLV has a better Quick ratio (7.86) than 68.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.86 | ||
| Quick Ratio | 7.86 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 14.72% over the past year.
EPS 1Y (TTM)14.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ENLV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.05% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.04%
EPS Next 2Y27.05%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ENLV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENLV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ENLV's earnings are expected to grow with 27.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.05%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ENLV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ENLIVEX THERAPEUTICS LTD
NASDAQ:ENLV (7/26/2024, 7:27:09 PM)
After market: 1.33 -0.03 (-2.21%)1.36
-0.03 (-2.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap28.10M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -83.71% | ||
| ROE | -96.79% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.86 | ||
| Quick Ratio | 7.86 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)14.72%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y47.04%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y